Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00307203 · ClinicalTrials.gov registry record · Phase 4
Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke
A Phase 4 study, sponsored by National Institute on Drug Abuse (NIDA).
- Completed
- Registry status
- Phase 4
- Development phase
- 51
- Enrollment target
NCT00307203 is a Phase 4 study that has completed, run by National Institute on Drug Abuse (NIDA). The registered enrollment target is 51 participants.
The verdict
NCT00307203, a Phase 4 study, has completed, sponsored by National Institute on Drug Abuse (NIDA).
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 51 participants
- Enrollment target
Study Summary
Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking. The purpose of this trial is to determine the safety and effectiveness of bupropion in treating individuals with schizophrenia who smoke.
Interventions
- DRUG nicotine replacement therapy
- BEHAVIORAL Cognitive Behavioral Group Therapy
- DRUG bupropion SR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 1998-08 |
| Est. Completion | 2004-02 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00307203
The ClinicalTrials.gov registry entry for NCT00307203 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute on Drug Abuse (NIDA), which has 335 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which nicotine replacement therapy is the first listed.
NCT00307203 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00307203 about?
NCT00307203 is a clinical study titled "Safety and Effectiveness of Sustained Release Bupropion in Treating Individuals With Schizophrenia Who Smoke". Many individuals with schizophrenia smoke cigarettes. Individuals in the schizophrenic population often find it difficult to quit smoking. The purpose of this trial is to determine the safety and effectiveness of bupropion in treating individuals with schizophrenia who smoke.
What is the current status of trial NCT00307203?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 51 participants. The study started on 1998-08. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00307203?
The interventions under investigation include: nicotine replacement therapy (DRUG), Cognitive Behavioral Group Therapy (BEHAVIORAL), bupropion SR (DRUG).
Who is sponsoring clinical trial NCT00307203?
This trial is sponsored by National Institute on Drug Abuse (NIDA), which has 335 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.